BACKGROUND: There are few medium-term virologic data in children from resource-limited settings taking adult fixed-dose-combination antiretroviral therapy (cART) without viral load monitoring. METHODS: CHAP2 (Children with HIV Antibiotic Prophylaxis 2) is a prospective cohort of Zambian children using d4T/3TC/NVP adult Triomune30 dosed according to WHO guidelines. RESULTS: A total of 103 children (19 with previous antiretroviral therapy) had follow-up >6 months. Median age at cART initiation was 8 years (IQR, 6-12) and CD4 8% (4-12). At 24 months, CD4% had increased by a median of 15% (7-25). For 74 children viral load was known/inferred: 51 of 74 (69%) had viral load <50 copies/mL (45 of 63 [71%] with no previous cART, 6 of 11 [55%] with previous cART; difference P = 0.30); 22 of 74 (30%) had viral load >1000 copies/mL. Of 26 children with resistance data, 25 (96%) had NNRTI resistance; 22 (84%) had M184V; 2 (8%) had Q151M; and 1 (4%) each had K65R, L74V, or K70E. Eight (31%) had > or =1 TAM. Those failing virologically with a genotypic sensitivity score of 0 for first-line therapy had a somewhat smaller increase in CD4% from baseline compared with those failing therapy with a genotypic sensitivity score >0 (+3 vs. +8, P = 0.13), and had somewhat lower CD4% at initiation of cART (2 vs. 11, P = 0.09). In 6 children with >1 resistance test, the estimated rate of accumulation of TAMs was 0.59/yr (95% confidence interval: 0.22-1.29). CONCLUSIONS: Twenty-four month virologic responses to cART were good. However, the rate of TAM accumulation in those with rebound was higher than reported in Western adult cohorts, and there was some indication of a detrimental effect of high level resistance on CD4% change from baseline.
BACKGROUND: There are few medium-term virologic data in children from resource-limited settings taking adult fixed-dose-combination antiretroviral therapy (cART) without viral load monitoring. METHODS: CHAP2 (Children with HIV Antibiotic Prophylaxis 2) is a prospective cohort of Zambian children using d4T/3TC/NVP adult Triomune30 dosed according to WHO guidelines. RESULTS: A total of 103 children (19 with previous antiretroviral therapy) had follow-up >6 months. Median age at cART initiation was 8 years (IQR, 6-12) and CD4 8% (4-12). At 24 months, CD4% had increased by a median of 15% (7-25). For 74 children viral load was known/inferred: 51 of 74 (69%) had viral load <50 copies/mL (45 of 63 [71%] with no previous cART, 6 of 11 [55%] with previous cART; difference P = 0.30); 22 of 74 (30%) had viral load >1000 copies/mL. Of 26 children with resistance data, 25 (96%) had NNRTI resistance; 22 (84%) had M184V; 2 (8%) had Q151M; and 1 (4%) each had K65R, L74V, or K70E. Eight (31%) had > or =1 TAM. Those failing virologically with a genotypic sensitivity score of 0 for first-line therapy had a somewhat smaller increase in CD4% from baseline compared with those failing therapy with a genotypic sensitivity score >0 (+3 vs. +8, P = 0.13), and had somewhat lower CD4% at initiation of cART (2 vs. 11, P = 0.09). In 6 children with >1 resistance test, the estimated rate of accumulation of TAMs was 0.59/yr (95% confidence interval: 0.22-1.29). CONCLUSIONS: Twenty-four month virologic responses to cART were good. However, the rate of TAM accumulation in those with rebound was higher than reported in Western adult cohorts, and there was some indication of a detrimental effect of high level resistance on CD4% change from baseline.
Authors: P Vaz; O Augusto; D Bila; E Macassa; A Vubil; I V Jani; R Pillon; P Sandstrom; D Sutherland; C Giaquinto; M R Jordan; S Bertagnolio Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Vijay B Bansode; Simon Aa Travers; Amelia C Crampin; Bagrey Ngwira; Neil French; Judith R Glynn; Grace P McCormack Journal: AIDS Res Ther Date: 2011-10-13 Impact factor: 2.250
Authors: Jean L Mbisa; Ravi K Gupta; Desire Kabamba; Veronica Mulenga; Moxmalama Kalumbi; Chifumbe Chintu; Chris M Parry; Diana M Gibb; Sarah A Walker; Patricia A Cane; Deenan Pillay Journal: Retrovirology Date: 2011-05-11 Impact factor: 4.602
Authors: Kate El Bouzidi; Dami Collier; Eleni Nastouli; Andrew J Copas; Robert F Miller; Ravindra K Gupta Journal: J Antimicrob Chemother Date: 2016-07-07 Impact factor: 5.790
Authors: Linda Barlow-Mosha; Victor Musiime; Mary-Ann Davies; Andrew J Prendergast; Philippa Musoke; George Siberry; Martina Penazzato Journal: J Int AIDS Soc Date: 2017-06-27 Impact factor: 5.396
Authors: Ruth L Goodall; David T Dunn; Peter Nkurunziza; Lincoln Mugarura; Theresa Pattery; Paula Munderi; Cissy Kityo; Charles Gilks; Pontiano Kaleebu; Deenan Pillay; Ravindra K Gupta Journal: J Antimicrob Chemother Date: 2017-05-01 Impact factor: 5.790
Authors: John Gregson; Pontiano Kaleebu; Vincent C Marconi; Cloete van Vuuren; Nicaise Ndembi; Raph L Hamers; Phyllis Kanki; Christopher J Hoffmann; Shahin Lockman; Deenan Pillay; Tulio de Oliveira; Nathan Clumeck; Gillian Hunt; Bernhard Kerschberger; Robert W Shafer; Chunfu Yang; Elliot Raizes; Rami Kantor; Ravindra K Gupta Journal: Lancet Infect Dis Date: 2016-12-01 Impact factor: 25.071